Pacritinib
Medication used to treat myelofibrosis / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Pacritinib?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis.[1][2] It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Vonjo |
Other names | SB1518 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H32N4O3 |
Molar mass | 472.589 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs.[2]